Приказ основних података о документу
Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells.
dc.creator | Buzharevski, Antonio | |
dc.creator | Paskaš, Svetlana | |
dc.creator | Sárosi, Menyhárt-Botond | |
dc.creator | Laube, Markus | |
dc.creator | Lönnecke, Peter | |
dc.creator | Neumann, Wilma | |
dc.creator | Murganić, Blagoje | |
dc.creator | Mijatović, Sanja | |
dc.creator | Maksimović-Ivanić, Danijela | |
dc.creator | Pietzsch, Jens | |
dc.creator | Hey-Hawkins, Evamarie | |
dc.date.accessioned | 2020-04-06T11:05:27Z | |
dc.date.available | 2020-04-06T11:05:27Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 2045-2322 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/32179835 | |
dc.identifier.uri | http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7076013 | |
dc.identifier.uri | https://radar.ibiss.bg.ac.rs/handle/123456789/3640 | |
dc.description.abstract | Owing to the involvement of cyclooxygenase-2 (COX-2) in carcinogenesis, COX-2-selective inhibitors are increasingly studied for their potential cytotoxic properties. Moreover, the incorporation of carboranes in structures of established anti-inflammatory drugs can improve the potency and metabolic stability of the inhibitors. Herein, we report the synthesis of carborane-containing derivatives of rofecoxib that display remarkable cytotoxic or cytostatic activity in the micromolar range with excellent selectivity for melanoma and colon cancer cell lines over normal cells. Furthermore, it was shown that the carborane-modified derivatives of rofecoxib showed different modes of action that were dependent on the cell type. | en |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173013/RS// | |
dc.relation | Deutscher Akademischer Austauschdienst | |
dc.relation | DFG (HE 1376/38-1; SA 2902/2-1) | |
dc.relation | Graduate School BuildMoNa | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | Scientific Reports | |
dc.title | Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells. | en |
dc.type | article | en |
dc.rights.license | BY | |
dcterms.abstract | Максимовић-Иванић, Данијела; Бузхаревски, Aнтонио; Паскаш, Светлана; Сáроси, Менyхáрт-Ботонд; Лаубе, Маркус; Лöннецке, Петер; Неуманн, Wилма; Мурганић, Благоје; Мијатовић, Сања; Пиетзсцх, Јенс; Хеy-Хаwкинс, Евамарие; | |
dc.rights.holder | © 2020, The Author(s). | |
dc.citation.issue | 1 | |
dc.citation.volume | 10 | |
dc.identifier.doi | 10.1038/s41598-020-59059-3 | |
dc.identifier.pmid | 32179835 | |
dc.identifier.scopus | 2-s2.0-85081989889 | |
dc.identifier.wos | 000562126100001 | |
dc.citation.apa | Buzharevski, A., Paskaš, S., Sárosi, M.-B., Laube, M., Lönnecke, P., Neumann, W., et al. (2020). Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells. Scientific Reports, 10(1), 4827. | |
dc.citation.vancouver | Buzharevski A, Paskaš S, Sárosi M-B, Laube M, Lönnecke P, Neumann W, Murganić B, Mijatović S, Maksimović-Ivanić D, Pietzsch J, Hey-Hawkins E. Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells. Sci Rep. 2020;10(1):4827. | |
dc.citation.spage | 4827 | |
dc.type.version | publishedVersion | |
dc.identifier.fulltext | https://radar.ibiss.bg.ac.rs/bitstream/id/6104/SciRep_2020_10_1_4827.pdf | |
dc.citation.rank | M21 |